CN107949387B - 用谷氨酰胺酶抑制剂治疗肺癌 - Google Patents

用谷氨酰胺酶抑制剂治疗肺癌 Download PDF

Info

Publication number
CN107949387B
CN107949387B CN201680032522.7A CN201680032522A CN107949387B CN 107949387 B CN107949387 B CN 107949387B CN 201680032522 A CN201680032522 A CN 201680032522A CN 107949387 B CN107949387 B CN 107949387B
Authority
CN
China
Prior art keywords
substituted
group
alkyl
arylalkyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680032522.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107949387A (zh
Inventor
F.帕拉蒂
M.G.沃尔克斯
M.L.M.罗德里格斯
张冬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calithera Biosciences Inc
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CN107949387A publication Critical patent/CN107949387A/zh
Application granted granted Critical
Publication of CN107949387B publication Critical patent/CN107949387B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680032522.7A 2015-04-06 2016-04-06 用谷氨酰胺酶抑制剂治疗肺癌 Expired - Fee Related CN107949387B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562143494P 2015-04-06 2015-04-06
US62/143494 2015-04-06
US201562149489P 2015-04-17 2015-04-17
US62/149489 2015-04-17
PCT/US2016/026127 WO2016164401A1 (en) 2015-04-06 2016-04-06 Treatment of lung cancer with inhibitors of glutaminase

Publications (2)

Publication Number Publication Date
CN107949387A CN107949387A (zh) 2018-04-20
CN107949387B true CN107949387B (zh) 2021-08-13

Family

ID=57015711

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680032522.7A Expired - Fee Related CN107949387B (zh) 2015-04-06 2016-04-06 用谷氨酰胺酶抑制剂治疗肺癌

Country Status (13)

Country Link
US (1) US10441587B2 (enExample)
EP (1) EP3280415A4 (enExample)
JP (2) JP6944377B2 (enExample)
KR (1) KR20170132333A (enExample)
CN (1) CN107949387B (enExample)
AU (1) AU2016246521B2 (enExample)
BR (1) BR112017021312A2 (enExample)
CA (1) CA2981762A1 (enExample)
EA (1) EA035354B1 (enExample)
IL (1) IL254876A0 (enExample)
MX (1) MX383034B (enExample)
SG (1) SG11201708153XA (enExample)
WO (1) WO2016164401A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
EP3954686A1 (en) 2012-11-16 2022-02-16 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
EA033919B1 (ru) 2014-04-30 2019-12-10 Пфайзер Инк. Соединённые циклоалкилом дигетероциклические производные
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
BR112019003533A2 (pt) 2016-08-25 2019-05-21 Calithera Biosciences Inc. terapia de combinação com inibidores de glutaminase
WO2018039441A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
EP3592354A4 (en) * 2017-03-10 2021-04-07 Calithera Biosciences, Inc. COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS
JP7188936B2 (ja) * 2018-08-21 2022-12-13 国立大学法人富山大学 抗炎症剤
JP7156856B2 (ja) * 2018-08-21 2022-10-19 国立大学法人富山大学 抗肥満剤
US20250275964A1 (en) * 2019-10-15 2025-09-04 Cornell University Methods of inhibiting liver-type glutaminase, gls2
US20240082158A1 (en) * 2020-05-21 2024-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition
CN111514460B (zh) * 2020-05-22 2021-12-14 西安交通大学 大气压冷等离子体在抑制谷氨酰胺酶活性方面的用途及酶抑制剂
CN113956233B (zh) * 2021-10-22 2023-06-06 南方医科大学 一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用
WO2023212718A2 (en) * 2022-04-29 2023-11-02 Cornell University Methods of treating a virus infection and methods of inhibiting viral replication

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089048A1 (en) * 2012-12-03 2014-06-12 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
CN104220070A (zh) * 2011-11-21 2014-12-17 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
CN107027291A (zh) * 2014-06-13 2017-08-08 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019519A (en) 1911-07-11 1912-03-05 Oscar Martin Polin Apparatus for making backing for teeth.
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AU2002305926A1 (en) 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
CN101951930A (zh) 2008-02-19 2011-01-19 阿奈斯特药品株式会社 对身体功能的恢复有用的口服或经肠组合物
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
MX2013005434A (es) 2010-11-18 2013-09-26 Deuteria Pharmaceuticals Inc 3´ - deutero - polidomida.
CN103030597B (zh) * 2011-09-30 2014-10-01 南昌滨西科技有限公司 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
US8604016B2 (en) * 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
EP2855698A4 (en) * 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc OBTAINING TO THE GLUTAMINE-TO-PYRUVAT SIGNAL PATH FOR THE TREATMENT OF CANCER ASSOCIATED WITH THE KRAS ONKOGEN
US9694015B2 (en) 2012-09-10 2017-07-04 Celgene Corporation Methods for the treatment of locally advanced breast cancer
WO2014043633A1 (en) 2012-09-17 2014-03-20 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
EP3954686A1 (en) * 2012-11-16 2022-02-16 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
HK1213889A1 (zh) 2012-11-21 2016-07-15 安吉奥斯医药品有限公司 殼氨醯胺酶抑制劑及使用方法
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
US20150258082A1 (en) 2014-03-14 2015-09-17 Francesco Parlati Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
WO2016077632A2 (en) 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
EP3277276B1 (en) * 2015-03-30 2020-11-04 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
WO2018039442A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Treatment of cancer with inhibitors of glutaminase
WO2018039441A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
BR112019003533A2 (pt) 2016-08-25 2019-05-21 Calithera Biosciences Inc. terapia de combinação com inibidores de glutaminase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104220070A (zh) * 2011-11-21 2014-12-17 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
WO2014089048A1 (en) * 2012-12-03 2014-06-12 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
CN107027291A (zh) * 2014-06-13 2017-08-08 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"非小细胞肺癌与结直肠癌KRAS 突变分析";郑神英;《基础医学与临床》;20130131;第33卷(第2期);第115-116页 *

Also Published As

Publication number Publication date
CN107949387A (zh) 2018-04-20
JP2021102662A (ja) 2021-07-15
EA035354B1 (ru) 2020-06-01
EP3280415A4 (en) 2018-12-26
KR20170132333A (ko) 2017-12-01
IL254876A0 (en) 2017-12-31
WO2016164401A8 (en) 2017-11-23
HK1254349A1 (zh) 2019-07-19
BR112017021312A2 (pt) 2018-06-26
AU2016246521B2 (en) 2020-07-09
EP3280415A1 (en) 2018-02-14
US10441587B2 (en) 2019-10-15
JP6944377B2 (ja) 2021-10-06
JP2018510884A (ja) 2018-04-19
EA201792227A1 (ru) 2018-11-30
WO2016164401A1 (en) 2016-10-13
AU2016246521A8 (en) 2019-08-15
AU2016246521A1 (en) 2017-11-02
MX2017012824A (es) 2018-05-15
SG11201708153XA (en) 2017-11-29
CA2981762A1 (en) 2016-10-13
US20160287585A1 (en) 2016-10-06
MX383034B (es) 2025-03-13

Similar Documents

Publication Publication Date Title
CN107949387B (zh) 用谷氨酰胺酶抑制剂治疗肺癌
JP6798890B2 (ja) グルタミナーゼ阻害剤との併用療法
JP6285950B2 (ja) グルタミナーゼの複素環式阻害剤を用いるがんの処置
WO2016014890A1 (en) Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
US20200038398A1 (en) Combination therapy with glutaminase inhibitors
EP3116872A1 (en) Combination therapy with glutaminase inhibitors
JP6954834B2 (ja) ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法
US10278968B2 (en) Combination therapy with glutaminase inhibitors
ES2991090T3 (es) Inhibidores de KDM4
CN115917324A (zh) 治疗癌症的方法
US20180055825A1 (en) Treatment of cancer with inhibitors of glutaminase
EP3703822A1 (en) Conjoint therapy with glutaminase inhibitors
US20230358726A1 (en) Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
HK1254349B (zh) 用谷氨酰胺酶抑制剂治疗肺癌
HK40010184A (en) Combination therapy with glutaminase inhibitors
HK1241274A1 (en) Combination therapy with glutaminase inhibitors
HK40020656A (en) Combination therapy with glutaminase inhibitors
HK1241274B (zh) 用谷氨酰胺酶抑制剂的组合疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1254349

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210813

CF01 Termination of patent right due to non-payment of annual fee